Pertussis epidemiological pattern and disease burden in Brazil: an analysis of national public health surveillance data

Hum Vaccin Immunother. 2020;16(1):61-69. doi: 10.1080/21645515.2019.1634991. Epub 2019 Jul 24.


Objective: We described pertussis epidemiological trends in Brazil between 2010 and 2015. We also assessed tetanus, diphtheria and acellular pertussis (Tdap) vaccine coverage among pregnant women from 2014, the year of the introduction of Tdap maternal immunization recommendation in Brazil, to 2016.Methods: Epidemiological data for incidence, prevalence, hospitalization, mortality, and maternal vaccination coverage were calculated based on the Brazilian public surveillance databases.Results: The epidemiological data analysis results showed that the pertussis average incidence rate (IR) was 2.19/100,000 inhabitants for all ages, with a peak in 2014 (4.03/100,000 inhabitants) and highest incidence in <1-year-old children (IR = 175.20/100,000). 97.6% of pertussis deaths (405/415) were in <1-year-old children. Maternal immunization coverage was 9.2% in 2014, 40.4% in 2015, and 33.8% in 2016.Conclusions: Pertussis incidence and pertussis-related deaths increased in Brazil from 2010 to 2014 and decreased in 2015. In the two years, 2015 and 2016 that followed the NIP recommendation, Tdap vaccination coverage of pregnant women was low and varying from region to region. More efforts and national plans would help increase awareness and maternal immunization coverage.

Keywords: Bordetella pertussis; Brazil; Tdap; epidemiology; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brazil / epidemiology
  • Child, Preschool
  • Cost of Illness*
  • Databases, Factual
  • Diphtheria-Tetanus-acellular Pertussis Vaccines / administration & dosage
  • Hospitalization / statistics & numerical data
  • Humans
  • Incidence
  • Infant
  • Public Health Surveillance*
  • Vaccination Coverage / statistics & numerical data
  • Whooping Cough / epidemiology*
  • Whooping Cough / mortality


  • Diphtheria-Tetanus-acellular Pertussis Vaccines

Grants and funding

GlaxoSmithKline Biologicals S.A. funded this study (GSK study identifier HO-16-17848) and all costs related to the development of related publications.